Bio-Rad: Anti-Idiotypic Antibodies for Pharmacokinetic Assays

Website: https://www.bio-rad-antibodies.com/biotherapeutic-antibodies-drug-discovery.html

Bio-Rad’s portfolio of recombinant monoclonal antibodies against marketed biologic drugs covers the following specificities:

Abatacept, Adalimumab, Alemtuzumab, Bevacizumab, Cemiplimab, Cetuximab, Daratumumab, Denosumab, Eculizumab, Etanercept, Golimumab, Infliximab, Ipilimumab, Natalizumab, Nivolumab, Omalizumab, Palivizumab, Panitumumab, Pembrolizumab, Pertuzumab, Ranibizumab, Rituximab, Secukinumab, Tocilizumab, Trastuzumab, Ustekinumab, Vedolizumab

Bio-Rad has developed these highly specific, high affinity anti-biotherapeutic antibodies to support your preclinical research, clinical trials and patient monitoring for original and biosimilar products.

We offer inhibitory anti-idiotypic antibodies for all the above biologics, ideal for PK assays measuring free drug. For several biologics, we also offer non-inhibitory anti-idiotypic antibodies for total drug assays, and drug-target complex specific antibodies for PK antigen capture assays avoiding the bridging format. Every antibody sequence is known, and recombinant production methods and stringent quality control mean you are assured of a consistent supply throughout the time course of your study. Our aim is to help you succeed with your bioanalytical assays:

Buy antibodies highly specific to your biologic or biosimilar
Design and optimize a selective and sensitive assay
Get translatable and reproducible results

View the Anti-Biotherapeutic Antibody Portfolio